To compare the safety and efficacy of triflusal vs aspirin in secondary stroke prevention.
- Aspirin (stroke prevention) Drug
Intervention Desc: Antiplatelet agent; inhibits thromboxane A2
- Triflusal (Disgren)Drug
Other Names: Disgren® Intervention Desc: Antiplatelet agent structurally related to aspirin
Randomized, double-blind, multicenter parallel trial involving 2113 patients at 43 centers.
Patients were randomized to receive either trifusal (600 mg OD) or aspirin (325 mg OD) administered for up to 3 years. Mean follow-up of 30 months.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Combined incidence of cardiovascular death, non-fatal stroke or non-fatal AMI.|